SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is seeing a massive surge after delivering a blowout quarterly earnings report that significantly outpaced revenue and profit expectations, fueled by strong data center and AI demand. The community is actively debating the stock's sudden re-rating and massive valuation gap, with many investors celebrating a historic turnaround while others remain skeptical of the underlying fundamentals versus the hype.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are surging in sympathy with Intel's earnings beat, as investors rotate capital into semiconductor stocks amid a broader rally in the AI hardware sector. The community is sharply divided, with bulls celebrating an explosive momentum-driven melt-up, while bears caution that the recent parabolic move and rapid sentiment shift signals potential blow-off top conditions.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors react to the appointment of a new CEO for its Tanbreez project and the recent consolidation of majority ownership in the Greenland-based rare earth asset. Community discussion is heavily focused on the company's strategic position in the Western critical minerals supply chain, with many debating the impact of recent institutional capital raises and speculating on future price performance as the project moves toward operational development.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor interest and extreme trading volume, fueled by confirmed purchase orders from Marvell and widespread speculation regarding its role in the AI data center supply chain. The community is actively discussing the companys transition from early-stage R&D to commercial manufacturing, with shareholders fiercely debating the valuation against the backdrop of an aggressive short squeeze.

Skillz, Inc. operates a mobile gaming platform that connects players in competition. It helps developers build franchises by enabling social competition in their games. Skillz hosts casual esports tournaments for mobile players worldwide. The company was founded by Andrew C Paradise and Casey Chafkin in 2012 and is headquartered in Las Vegas, NV.

Skillz Inc - Ordinary Shares - Class A

Skillz Inc

Skillz Inc. is experiencing significant volatility and trending across social media following a major legal victory where a federal jury awarded the company over $1 billion in damages and disgorgement against rival Papaya Gaming. The community is heavily focused on the potential for a massive short squeeze due to the stock's low float, institutional backing, and intense debate over whether the company can successfully collect the court-awarded funds.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is experiencing intense volatility as investors react to the news of cannabis rescheduling, with the community expressing frustration over aggressive sell-offs despite the potential long-term tax and banking benefits. While many traders remain focused on historical price levels and potential short squeezes, a significant portion of the community is voicing concerns over perceived market manipulation and dilution, leading to a deep divide between those holding for a long-term sector recovery and those skeptical of institutional motives.

ASGN Incorporated engages in the provision of information technology services and solutions. It operates through the Commercial and Federal Government segments. The Commercial segment involves the provision of consulting, creative digital marketing, and permanent placement services. The Federal Government segment provides mission-critical solutions. The company was founded on December 30, 1985 and is headquartered in Glen Allen, VA.

ASGN Inc

ASGN Inc. is trending as investors digest a significant price decline following disappointing quarterly earnings and guidance. Community sentiment is deeply polarized, with some traders viewing the pullback as a buying opportunity based on the company's valuation and pending rebrand to Everforth, while others are calling for regulatory investigations into alleged market manipulation and poor financial performance.

Seeker is building a decentralized mobile ecosystem designed to challenge entrenched mobile incumbents through its TEEPin network architecture and community governance. It aims to solve the pain points of centralized app store gatekeeping, lack of developer freedom, and restricted user access to crypto applications. The vision is to create a community-owned platform with decentralized governance, no gatekeepers, direct developer-user access, and TEEPin security architecture.

Seeker

Seeker ($SKR) is garnering significant community attention following its recent exchange listings and its role as the native token for the Solana Mobile smartphone ecosystem. Investors are actively discussing the token's utility in staking and governance, with many closely tracking volume patterns and potential price catalysts amid high volatility.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following the announcement of its acquisition of LivePerson, a move investors are evaluating as a strategic effort to consolidate voice and digital messaging capabilities into a unified omnichannel AI platform. While bullish community members highlight the immediate expansion of the enterprise customer base and cross-selling potential, the stock is seeing heightened volatility as traders weigh the integration risks and the impact of the deal on the company's valuation.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is surging amid high trading volume as investors react to strengthening technical signals and persistent buyout speculation surrounding the company's Briumvi commercial progress. The community remains focused on potential M&A activity and upcoming clinical readouts, with many traders discussing the stock's positioning against recent sector-wide deals and CEO Michael Weisss performance-based incentives.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Short Interest in C4 Therapeutics, Inc. (NASDAQ:CCCC) Grows By 19.4%

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totaling 16,157,271 shares, an increase of 19.4% from the March 15th total of 13,534,910 shares. Approximately 18.1% of the...

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Average Recommendation of "Moderate Buy" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the firm...

C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies

C4 Therapeutics partners with Roche to develop cancer-fighting DACs. CCCC eligible for $1B+ in milestones plus royalties. See the details.read more...

<ul class="summary-bullets"><li>C4&nbsp;Therapeutics is also eligible to earn tiered royalties on future product sales.</li><li>C4 and Roche will focus on developing emerging cancer treatments using degrader-antibody conjugates and targeted protein degradation processes.</li><li>The companies will work together on two programs to develop the new cancer treatments.&nbsp;</li></ul>Shares of C4 Therapeutics, Inc. (CCCC) reversed pre-market gains to edge 2% lower on Thursday, after the company expanded its partnership with Swiss pharmaceutical company Roche to develop cancer treatments.C4 Therapeutics said the new collaboration will focus on developing emerging cancer treatments using&nbsp;a degrader-antibody conjugate (DAC) and targeted protein degradation (TPD) processes.&nbsp;“Our new collaboration leverages C4T’s ability to design highly catalytic and selective degraders, as well as degrader payloads for DACs, alongside Roche’s extensive experience developing ADCs with specific binding. Together, these capabilities build a powerful new modality that can offer transformative medicines for patients,” said Andrew Hirsch, President and CEO of C4 Therapeutics.<h2 class="st-heading-2">C4 Could Earn Up To $1 Billion</h2>The companies will work together on two programs to develop new cancer treatments. C4&nbsp;Therapeutics&nbsp;will design the drug components using its TORPEDO platform, which uses advanced tools and AI to target harmful proteins.&nbsp;&nbsp;Roche will create the antibodies and combine them with the drug. Roche will also handle testing, development, and sales.&nbsp;C4&nbsp;Therapeutics&nbsp;will receive a $20 million upfront payment for the two programs, with the potential for additional payments if Roche opts to include a third target. The agreement also includes near-term discovery milestones, while total milestone payments could exceed $1 billion. Additionally, the firm is eligible to earn tiered royalties on future product sales.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the reversal after the opening bell, retail sentiment on Stocktwits for <a href="https://stocktwits.com/symbol/CCCC">CCCC</a> flipped to ‘extremely bullish’ from&nbsp; ‘bearish’ a day earlier, amid ‘high’ message volumes.One user said that, based on the contract, the stock should be around $4 to $5. It is currently around $2.8.<stembedurl>https://stocktwits.com/intrader/message/649802478</stembedurl>Another bullish user highlighted the company’s runway until 2028.<stembedurl>https://stocktwits.com/intrader/message/649810594</stembedurl>The stock has shot up more than 35% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CCCC Stock Reverses Pre-Market Gains After Roche Tie-Up To Develop Cancer Treatments - Retail Sees Strong Upside

Under the agreement, C4 Therapeutics will receive a $20 million upfront payment and could earn over $1 billion in milestone payments.

Equity

C4 Therapeutics, Inc. (NASDAQ:CCCC) Short Interest Update

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the target of a large increase in short interest during the month of March. As of March 13th, there was short interest totaling 13,534,910...

Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?

Here is how C4 Therapeutics, Inc. (CCCC) and Align Technology (ALGN) have performed compared to their sector so far this year.

C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) have been given an average rating of "Moderate Buy" by the seven ratings firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have i...

C4 Therapeutics, Inc. (NASDAQ:CCCC - Get Free Report) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling...

C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab

C4 Therapeutics (NASDAQ:CCCC) outlined near-term clinical plans for its targeted protein degradation pipeline during a presentation at Barclays' 28th Annual Global Healthcare Conference, highlighting...

C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference

C4 Therapeutics (NASDAQ:CCCC) used a presentation at TD Cowen's 46th Annual Healthcare Conference to outline its near- and mid-term clinical plans, emphasizing its lead multiple myeloma program...

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.25	--	--	N/A
Q4 '25	-$0.30	-$0.18	39.02%	BEAT
Q3 '25	-$0.41	-$0.44	-8.45%	MISSED
Q2 '25	-$0.38	-$0.37	3.65%	BEAT
Q1 '25	-$0.44	-$0.37	16.29%	BEAT

CCCC
C4 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CCCC News

CCCCC4 Therapeutics Inc